CRF1 Not Glucocorticoid Receptors Mediate Prepulse Inhibition Deficits in Mice Overexpressing CRF

Biological Psychiatry

Volumn 63, Issue 4, 2008, Pages 360-368

  Groenink, Lucianne ^a   Dirks, Anneloes ^a   Verdouw, P Monika ^a   de Graaff, Marijke ^a   Peeters, Bernard W ^b   Millan, Mark J ^c   Olivier, Berend ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NV ORGANON   (Netherlands)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Corticosterone; CRF (corticotropin releasing factor); CRH (corticotropin releasing hormone); major depression; psychosis; sensorimotor gating

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; DMP 695; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; HORMONE ANTAGONIST; STEROID;

ADRENALECTOMY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; GENOTYPE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RECEPTOR INTRINSIC ACTIVITY; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; STARTLE REFLEX; TRANSGENIC MOUSE; ANIMAL; AUDITORY STIMULATION; DISEASE MODEL; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; INFUSION; MAJOR DEPRESSION; MALE;

ACOUSTIC STIMULATION; ADRENALECTOMY; ANIMALS; BENZODIOXOLES; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENOTYPE; HORMONE ANTAGONISTS; INFUSIONS, PARENTERAL; MALE; MICE; MICE, TRANSGENIC; MIFEPRISTONE; PSYCHOTIC DISORDERS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, GLUCOCORTICOID; STARTLE REACTION; STEROIDS;

EID: 38549172912     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.06.002     Document Type: Article

References (77)

1. Reus V.I., and Wolkowitz O.M. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs 10 (2001) 1789-1796
2. Gold P.W., and Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states. Mol Psychiatry 7 (2002) 254-275
3. Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110 (2006) 135-370
4. Anton R.F. Urinary free cortisol in psychotic depression. Biol Psychiatry 22 (1987) 24-34
5. Rush A.J., Giles D.E., Schlesser M.A., Orsulak P.J., Parker Jr. C.R., Weissenburger J.E., et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 57 (1996) 470-484
6. Keller J., Flores B., Gomez R.G., Solvason H.B., Kenna H., Williams G.H., et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 60 (2006) 275-281
7. Belanoff J.K., Flores B.H., Kalezhan M., Sund B., and Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21 (2001) 516-521
8. Izzo E., Sanna P.P., and Koob G.F. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Pharmacol Biochem Behav 81 (2005) 701-708
9. Schatzberg A.F., Rothschild A.J., Langlais P.J., Bird E.D., and Cole J.O. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 19 (1985) 57
10. Belanoff J.K., Rothschild A.J., Cassidy F., DeBattista C., Baulieu E.E., Schold C., et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 52 (2002) 386-392
11. Wang B., Shaham Y., Zitzman D., Azari S., Wise R.A., and You Z.B. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: A role in stress-induced relapse to drug seeking. J Neurosci 25 (2005) 5389-5396
12. Flores B.H., Kenna H., Keller J., Solvason H.B., and Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31 (2006) 628-636
13. Simpson G.M., El Sheshai A., Loza N., Kingsbury S.J., Fayek M., Rady A., et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 66 (2005) 598-602
14. Rothschild A.J. Placebo response in psychotic depression. J Clin Psychiatry 66 (2005) 1615 author reply 1615-1616
15. Rubin R.T., and Carroll B.J. Claims for mifepristone in neuropsychiatric disorders: Commentary on DeBattista and Belanoff, and Neigh and Nemeroff. Trends Endocrinol Metab 17 (2006) 384-385 author reply 387-389
16. Heinrichs S.C., and Koob G.F. Corticotropin-releasing factor in brain: A role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 311 (2004) 427-440
17. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 4 (2003) 46-50
18. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 70 (2003) 83-244
19. Hillhouse E.W., and Grammatopoulos D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: Implications for physiology and pathophysiology. Endocr Rev 27 (2006) 260-286
20. Steckler T., and Dautzenberg F.M. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-an update. CNS Neurol Disord Drug Targets 5 (2006) 147-165
21. Nielsen D.M. Corticotropin-releasing factor type-1 receptor antagonists: The next class of antidepressants?. Life Sci 78 (2006) 909-919
22. Behan D.P., Grigoriadis D.E., Lovenberg T., Chalmers D., Heinrichs S., Liaw C., et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: Implications for the treatment of CNS disorders (see comments). Mol Psychiatry 1 (1996) 265
23. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428 (2000) 191-212
24. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., and De S.E.B. Corticotrophin-releasing factor receptors: From molecular biology to drug design. Trends Pharmacol Sci 17 (1996) 166
25. Hasler G., Drevets W.C., Manji H.K., and Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 29 (2004) 1765-1781
26. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 34 (2000) 171-181
27. Herringa R.J., Roseboom P.H., and Kalin N.H. Decreased amygdala CRF-binding protein mRNA in post-mortem tissue from male but not female bipolar and schizophrenic subjects. Neuropsychopharmacology 31 (2006) 1822-1831
28. Moffett M.C., and Goeders N.E. CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology (Berl) 190 (2007) 171-180
29. Wang J., Fang Q., Liu Z., and Lu L. Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in rats. Psychopharmacology (Berl) 185 (2006) 19-28
30. Altamura A.C., Boin F., and Maes M. HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 10 (1999) 1-4
31. Park S.W., Lee S.K., Kim J.M., Kang H.C., Yoon J.S., and Kim Y.H. Quetiapine regulates the stress-induced increase in corticotropin-releasing factor mRNA expression in the rat hypothalamus. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 357-360
32. Sautter F.J., Bissette G., Wiley J., Manguno-Mire G., Schoenbachler B., Myers L., et al. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 54 (2003) 1382-1388
33. Graham F.K. Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 12 (1975) 238-248
34. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
35. Swerdlow N.R., Geyer M.A., and Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. Psychopharmacology (Berl) 156 (2001) 194-215
36. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
37. Dirks A., Groenink L., Schipholt M.I., van der Gugten J., Hijzen T.H., Geyer M.A., et al. Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51 (2002) 583-590
38. Conti L.H., Costill J.E., Flynn S., and Tayler J.E. Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain. Behav Neurosci 119 (2005) 1052-1060
39. Risbrough V.B., Hauger R.L., Roberts A.L., Vale W.W., and Geyer M.A. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24 (2004) 6545-6552
40. Vinkers C.H., Risbrough V.B., Geyer M.A., Caldwell S., Low M.J., and Hauger R.L. Role of dopamine D(1) and D(2) receptors in CRF-induced disruption of sensorimotor gating. Pharmacol Biochem Behav 86 (2007) 550-558
41. de Groote L., Penalva R.G., Flachskamm C., Reul J.M., and Linthorst A.C. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J Neurochem 94 (2005) 45-56
42. Kirby L.G., Rice K.C., and Valentino R.J. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22 (2000) 148-162
43. Ingram N., Martin S., Wang J.H., van der Laan S., Loiacono R., and van den Buuse M. Interaction of corticosterone and nicotine in regulation of prepulse inhibition in mice. Neuropharmacology 48 (2005) 80-92
44. Stevens K.E., Bullock A.E., and Collins A.C. Chronic corticosterone treatment alters sensory gating in C3H mice. Pharmacol Biochem Behav 69 (2001) 359-366
45. van den Buuse M., Morris M., Chavez C., Martin S., and Wang J. Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice. Br J Pharmacol 142 (2004) 543-550
46. Aronsson M., Fuxe K., Dong Y., Agnati L.F., Okret S., and Gustafsson J.A. Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc Natl Acad Sci U S A 85 (1988) 9331-9335
47. Pesini P., Detheux M., Parmentier M., and Hokfelt T. Distribution of a glucocorticoid-induced orphan receptor (JP05) mRNA in the central nervous system of the mouse. Brain Res Mol Brain Res 57 (1998) 281-300
48. Piazza P.V., Barrot M., Rouge-Pont F., Marinelli M., Maccari S., Abrous D.N., et al. Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proc Natl Acad Sci U S A 93 (1996) 15445-15450
49. Harfstrand A., Fuxe K., Cintra A., Agnati L.F., Zini I., Wikstrom A.C., et al. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc Natl Acad Sci U S A 83 (1986) 9779-9783
50. Meijer O.C., Van Oosten R.V., and De Kloet E.R. Elevated basal trough levels of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor expression in adrenally intact rats: Implication for the pathogenesis of depression. Neuroscience 80 (1997) 419-426
51. Groenink L., Dirks A., Verdouw P.M., Schipholt M., Veening J.G., van der Gugten J., et al. HPA axis dysregulation in mice overexpressing corticotropin releasing hormone. Biol Psychiatry 51 (2002) 875-881
52. Groenink L., Pattij T., De Jongh R., Van der Gugten J., Oosting R.S., Dirks A., et al. 5-HT1A receptor knockout mice and mice overexpressing corticotropin-releasing hormone in models of anxiety. Eur J Pharmacol 463 (2003) 185-197
53. Dirks A., Groenink L., Westphal K.G., Olivier J.D., Verdouw P.M., van der Gugten J., et al. Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 1790-1798
54. Dirks A., Groenink L., Bouwknecht J.A., Hijzen T.H., Van Der Gugten J., Ronken E., et al. Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur J Neurosci 16 (2002) 1751-1760
55. Borski R.J. Nongenomic membrane actions of glucocorticoids in vertebrates. Trends Endocrinol Metab 11 (2000) 427-436
56. Makara G.B., and Haller J. Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications. Prog Neurobiol 65 (2001) 367-390
57. Korte S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 25 (2001) 117-142
58. Koenig H.N., and Olive M.F. The glucocorticoid receptor antagonist mifepristone reduces ethanol intake in rats under limited access conditions. Psychoneuroendocrinology 29 (2004) 999-1003
59. Moldow R.L., Beck K.D., Weaver S., and Servatius R.J. Blockage of glucocorticoid, but not mineralocorticoid receptors prevents the persistent increase in circulating basal corticosterone concentrations following stress in the rat. Neurosci Lett 374 (2005) 25-28
60. De Kloet E.R., De Kock S., Schild V., and Veldhuis H.D. Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. Neuroendocrinology 47 (1988) 109-115
61. Bertagna X., Escourolle H., Pinquier J.L., Coste J., Raux-Demay M.C., Perles P., et al. Administration of RU 486 for 8 days in normal volunteers: Antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 78 (1994) 375-380
62. Hummel K.P. Accessory adrenal cortical nodules in the mouse. Anat Rec 132 (1958) 281-295
63. Brinks V., van der Mark M.H., de Kloet E.R., and Oitzl M.S. Differential MR/GR activation in mice results in emotional states beneficial or impairing for cognition. Neural Plasticity 2007 (2007) (doi:10.1155/2007/90163). Available at: http://www.hindawi.com/GetArticle.aspx?doi=10.1155/2007/90163&e=cta. Accessed June 15, 2007
64. Usuku T., Nishi M., Morimoto M., Brewer J.A., Muglia L.J., Sugimoto T., et al. Visualization of glucocorticoid receptor in the brain of green fluorescent protein-glucocorticoid receptor knockin mice. Neuroscience 135 (2005) 1119-1128
65. Arvaniti K., Huang Q., and Richard D. Effects of leptin and corticosterone on the expression of corticotropin-releasing hormone, agouti-related protein, and proopiomelanocortin in the brain of ob/ob mouse. Neuroendocrinology 73 (2001) 227-236
66. Ni X., and Nicholson R.C. Steroid hormone mediated regulation of corticotropin-releasing hormone gene expression. Front Biosci 11 (2006) 2909-2917
67. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., et al. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93 (1996) 10477-10482
68. Gilligan P.J., and Li Y.W. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr Opin Drug Discov Devel 7 (2004) 487-497
69. Gilligan P.J., Robertson D.W., and Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents. J Med Chem 43 (2000) 1641-1660
70. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., and Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25 (2001) 585-600
71. Lejeune F., and Millan M.J. The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. Eur J Pharmacol 464 (2003) 127-133
72. Griebel G., Perrault G., and Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 138 (1998) 55-66
73. Kehne J.H., Coverdale S., McCloskey T.C., Hoffman D.C., and Cassella J.V. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39 (2000) 1357-1367
74. Lorrain D.S., Baccei C.S., Correa L.D., and Bristow L.J. Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels. Neuropharmacology 48 (2005) 927-935
75. Gannon R.L., and Millan M.J. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms. Brain Res 1083 (2006) 96-102
76. Conti L.H. Characterization of the effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in Brown Norway and Wistar-Kyoto rats. Eur J Pharmacol 507 (2005) 125-134
77. Valentino R.J., and Commons K.G. Peptides that fine-tune the serotonin system. Neuropeptides 39 (2005) 1-8